Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma

Rachel Lubong Sabado1,2, Anna Pavlick1, Sacha Gnatic2-3, Crystal M. Cruz1, Isabelita Vengco1, Farah Hasan1, Meredith Spadaccia1, Farbod Darvishian1, Luis Chiriboga1, Rose Marie Holman1, Juliet Escalon1, Caroline Muren1, Crystal Escano1, Ethel Yepes1, Dunbar Sharpe1, John P. Vasilakos5, Linda Rolnitzsky6, Judith D. Goldberg6, John Mandeli2, Sylvia Adams1, Achim Jungbluth7, Linda Pan3, Ralph Venhaus3, Patrick A. Ott1,8, and Nina Bhardwaj1,2,4

Abstract

The Toll-like receptor (TLR) 7/8 agonist resiquimod has been used as an immune adjuvant in cancer vaccines. We evaluated the safety and immunogenicity of the cancer testis antigen NY-ESO-1 given in combination with Montanide (Seppic) with or without resiquimod in patients with high-risk melanoma. In part I of the study, patients received 100 μg of full-length NY-ESO-1 protein emulsified in 1.25 mL of Montanide (day 1) followed by topical application of 1,000 mg of 0.2% resiquimod gel on days 1 and 3 (cohort 1) versus days 1, 3, and 5 (cohort 2) of a 21-day cycle. In part II, patients were randomized to receive 100-μg NY-ESO-1 protein plus Montanide (day 1) followed by topical application of placebo gel ([arm A; n = 8] or 1,000 mg of 0.2% resiquimod gel [arm B; n = 12]) using the dosing regimen established in part I. The vaccine regimens were generally well tolerated. NY-ESO-1–specific humoral responses were induced or boosted in all patients, many of whom had high titer antibodies. In part II, 16 of 20 patients in both arms had NY-ESO-1–specific CD4+ T-cell responses. CD8+ T-cell responses were only seen in 3 of 12 patients in arm B. Patients with TLR7 SNP rs179008 had a greater likelihood of developing NY-ESO-1–specific CD8+ responses. In conclusion, NY-ESO-1 protein in combination with Montanide with or without topical resiquimod is safe and induces both antibody and CD4+ T-cell responses in the majority of patients; the small proportion of CD8+ T-cell responses suggests that the addition of topical resiquimod to Montanide is not sufficient to induce consistent NY-ESO-1–specific CD8+ T-cell responses. Cancer Immunol Res; 3(3); 278–87. ©2015 AACR.

Introduction

NY-ESO-1 is considered widely a suitable tumor antigen for vaccination due to its presence in many tumor types, its highly restricted expression in normal tissues, and the ability to induce strong spontaneous humoral and cellular immune responses (1). In vitro and in vivo studies have shown that NY-ESO-1 is immunogenic with particular regions of the protein specifically targeted by antibodies as well as CD4+ and CD8+ T cells. Although clinical trials have demonstrated that patients have immunity to NY-ESO-1, only a small number of clinical trials have been observed in patients with advanced disease. Induction of integrated immune responses to NY-ESO-1 consisting of humoral and CD4+ and CD8+ T-cell responses correlated with clinical benefit in patients with melanoma who received anti-CTLA4 inhibitors (2). Therefore, to achieve effective CD4+ and CD8+ T-cell priming, we vaccinated individuals with the full-length recombinant NY-ESO-1 protein and evaluated the addition of Toll-like receptor (TLR) adjuvants to the vaccine.

TLRs are a family of highly conserved transmembrane receptors that recognize specific molecular patterns in microbial components (3). Stimulation of different TLRs induces distinct patterns of gene expression, not only activating innate immunity but also directing adaptive immunity, such as the induction of a Th1 helper 1 (Th1) cell response that is necessary for antitumor immune responses (4). TLR agonists control antigen-presenting cells (APC), in particular dendritic cells (DC), by triggering their maturation program, including upregulation of the expression of human leukocyte antigen (HLA) and costimulatory molecules and secretion of cytokines such as TNFα, IL-6, IL-12, and IFNγ (5). In addition, animal models have shown that TLR agonists can improve the efficacy of vaccines targeting self-antigens by activation of innate immune cells and production of inflammatory cytokines (6) and alter the immunosuppressive function of regulatory T cells (Treg; ref. 7). Consequently, TLR agonists have been recognized as promising vaccine adjuvants and have been developed for use as adjuvants for cancer vaccines in clinical trials.
(8–10). However, there is a paucity of controlled studies assessing the potency of adding TLR agonists to standard adjuvants such as Montanide (Seppic).

Previously, we examined the safety and immunogenicity of the topical TLR7 agonist imiquimod (Aldara; 3M) as an adjuvant to NY-ESO-1 protein vaccination in patients with melanoma. Although the vaccine, which was given without Montanide, induced NY-ESO-1–specific antibodies and CD4+ T-cell responses, no detectable CD8+ T-cell responses were observed (11). Therefore, we sought to improve upon the results of the study using another TLR agonist. Resiquimod is a TLR7/8 agonist that is chemically related to imiquimod but has been shown to stimulate a more potent immune response than imiquimod (12). In vitro studies using resiquimod have shown that it can activate DC maturation by increasing costimulatory molecule expression and cytokine production, and skew a Th1 cytokine profile, consequently enhancing humoral and cellular immune responses (13, 14). More recently, resiquimod has been shown to promote cross-presentation of exogenous antigens, resulting in the efficient induction of antigen-specific CD8+ T-cell responses (15). Results from animal studies have confirmed the ability of resiquimod to activate DCs (16), bias immune responses toward a predominance of Th1 cells (17), and enhance antigen-specific CD8+ T-cell responses that can inhibit tumor growth (18, 19). Therefore, the capacity of resiquimod to induce local activation of immune cells, stimulate the production of proinflammatory cytokines, and enhance antigen presentation by DCs leading to activation of effective cellular responses are features that support its potential as a cancer vaccine adjuvant (20).

In this randomized study, we evaluated the safety and immunogenicity of vaccination with NY-ESO-1 protein emulsified in Montanide ISA-51 VG when given with or without resiquimod in patients with resected melanoma [American Joint Committee on Cancer (AJCC) stages IIB, III, and IV]. Patients with histologically confirmed resected malignant melanoma [American Joint Committee on Cancer (AJCC) stages II, III, and IV] were eligible. Tumor NY-ESO-1 expression was assessed by immunohistochemistry as previously described (21), but was not required for study entry. The study (NCI00821652) was approved by the New York University School of Medicine (New York, NY) Institutional Review Board, and written informed consent was obtained from all patients before enrollment.

In part I of the study, the safety of two different dosing regimens of resiquimod was assessed in two cohorts of 3 patients each. Subjects received four 3-week cycles of subcutaneous (s.c.) injections with 100 μg of recombinant human NY-ESO-1 protein (Ludwig Institute for Cancer Research, Boston, MA) emulsified in 1.25 mL Montanide (day 1) followed by topical application of 1,000 mg of resiquimod (3M Pharmaceuticals; 0.2%) gel to the vaccination site on days 1 and 3 (cohort 1) and days 1, 3, and 5 (cohort 2), respectively (Fig. 1). In part II of the study, patients were randomized in a blinded fashion to receive 100 μg NY-ESO-1 protein emulsified in 1.25 mL Montanide (day 1) followed by topical application of placebo gel (arm A; n = 8) or 1,000 mg of 0.2% resiquimod gel (arm B; n = 12) on days 1, 3, and 5 as established in part I (Fig. 1). Study arm assignments were unblinded after completion of the study and immune monitoring.

Blood samples

Blood samples were collected at baseline and day 8 of each cycle (weeks 1, 4, 7, and 10) and during the first follow-up visit at weeks 12 to 14. Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood by Ficoll centrifugation and frozen in aliquots using pooled human serum (90%) and DMSO (10%). Plasma from each time point was also frozen.

**Materials and Methods**

**Study design, patients, and treatment plan**

This is a two-part study with resiquimod dose escalation in part I and randomization to resiquimod versus placebo in part II. The primary objectives of the study were safety of the vaccine regimen and assessment of humoral and cellular responses to NY-ESO-1. Patients with histologically confirmed resected malignant melanoma [American Joint Committee on Cancer (AJCC) stages II, III, and IV] were eligible. Tumor NY-ESO-1 expression was assessed by immunohistochemistry as previously described (21), but was not required for study entry. The study (NCI00821652) was approved by the New York University School of Medicine (New York, NY) Institutional Review Board, and written informed consent was obtained from all patients before enrollment.

In part I of the study, the safety of two different dosing regimens of resiquimod was assessed in two cohorts of 3 patients each. Subjects received four 3-week cycles of subcutaneous (s.c.) injections with 100 μg of recombinant human NY-ESO-1 protein (Ludwig Institute for Cancer Research, Boston, MA) emulsified in 1.25 mL Montanide (day 1) followed by topical application of 1,000 mg of resiquimod (3M Pharmaceuticals; 0.2%) gel to the vaccination site on days 1 and 3 (cohort 1) and days 1, 3, and 5 (cohort 2), respectively (Fig. 1). In part II of the study, patients were randomized in a blinded fashion to receive 100 μg NY-ESO-1 protein emulsified in 1.25 mL Montanide (day 1) followed by topical application of placebo gel (arm A; n = 8) or 1,000 mg of 0.2% resiquimod gel (arm B; n = 12) on days 1, 3, and 5 as established in part I (Fig. 1). Study arm assignments were unblinded after completion of the study and immune monitoring.

**Blood samples**

Blood samples were collected at baseline and day 8 of each cycle (weeks 1, 4, 7, and 10) and during the first follow-up visit at weeks 12 to 14. Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood by Ficoll centrifugation and frozen in aliquots using pooled human serum (90%) and DMSO (10%). Plasma from each time point was also frozen.

**Figure 1.**

Study design. In part I of the study, the safety of two different dosing regimens of resiquimod in two cohorts of 3 patients each was assessed. Subjects received four 3-week cycles of subcutaneous (s.c.) injections of 100 μg of recombinant human NY-ESO-1 protein emulsified in 1.25 mL Montanide (day 1) followed by topical application of 1,000 mg of resiquimod (0.2%) gel on days 1 and 3 (cohort 1) and days 1, 3, and 5 (cohort 2), respectively. In part II of the study, patients were randomized in a blinded fashion to receive an s.c. injection of 100 μg NY-ESO-1 protein emulsified in 1.25 mL Montanide (day 1) followed by topical application of placebo gel (arm A; n = 8) or 1,000 mg of 0.2% resiquimod gel (Arm-B; n = 12) as determined in part I.

**PART I**

**Stage IIB, C, III, and IV resected melanoma**

- **Cohort 1:** n = 3
  - 100 μg NY-ESO-1 protein + 1.25 mL Montanide + 1,000 mg 0.2% resiquimod (2x weekly)

- **Cohort 2:** n = 3
  - 100 μg NY-ESO-1 protein + 1.25 mL Montanide + 1,000 mg 0.2% resiquimod (3x weekly)

**PART II**

**Stage IIB, C, III, and IV resected melanoma**

- **Arm A:** n = 8
  - 100 μg NY-ESO-1 protein + 1.25 mL Montanide + placebo gel

- **Arm B:** n = 12
  - 100 μg NY-ESO-1 protein + 1.25 mL Montanide + 1,000 mg 0.2% resiquimod (3x weekly)
Humoral responses

Patient plasma samples were analyzed by ELISA for seroreactivity against recombinant NY-ESO-1 protein (1 μg/mL) as well as three individual overlapping long peptides (68–mers, 1 μmol/L each) covering the NY-ESO-1 sequences as previously described (22). Synthetic long peptides were used to confirm specificity for NY-ESO-1 plasma antibodies and for approximate epitope mapping. A reciprocal titer was calculated for each plasma sample as the maximal dilution still significantly reacting to a specific antigen. This value was extrapolated by determining the intersection of a linear trend regression with a cutoff value. The cutoff was defined as ten times the average of OD values from the first four dilutions of a negative control pool comprising five healthy donor sera. In each assay, sera of patients with known presence or absence of specific reactivity were used as controls.

Titers >100 were considered reactive, and specificity was determined by comparing reactivity to control antigens and to the NY-ESO-1 peptides.

T-cell assays

T-cell responses to NY-ESO-1 were evaluated after in vitro stimulations (IVS) with overlapping pools of NY-ESO-1 peptides. T cells were restimulated with the overlapping pools of NY-ESO-1 peptides and then stained for IFNγ, TNFα, and IL2 and analyzed by flow cytometry. IVS were performed with some modifications as described previously (11). PBMCs were thawed and cultured overnight in 5% PHS (Valley Biomedicals) in RPMI (Gibco), then separated into CD4⁺, CD8⁺, and CD4⁻/CD8⁻ (APC) fractions using Dynal Beads (Invitrogen). For the CD25-depletion experiments, CD25⁺ cells were initially depleted from PBMCs before positive selection of CD4⁺ and CD8⁺ fractions. Each fraction was then washed and resuspended in 5% PHS/RPMI containing 10 U/mL IL2 (R&D Systems) and 10 ng/mL IL7 (R&D Systems). CD4⁺ and CD8⁺ cells (500,000 to 1 million cells/well) were cocultured separately for 14 to 20 days with APCs stimulated with pooled NY-ESO-1 overlapping peptides covering the NY-ESO-1 protein (1 μg/mL each) in a 96-well round-bottom plate. Medium and cytokines were replenished every 2 to 3 days.

IVS CD8⁺ T-cell cultures were tested on day 14 and CD4⁺/CD8⁻ T-cell cultures on day 21 for reactivity to NY-ESO-1 by intracellular cytokine staining (ICS). T-cell cultures were harvested, washed, and replated in 5% PHS/RPMI medium in a 96-well V-bottom plate. A pool of all 17 NY-ESO-1 peptides (1 μg/mL each) was added to one of the wells. Control wells containing DMSO, MOG, CMV, and PMA/ionomycin were included. Epitope mapping was done using individual NY-ESO-1 peptides. For all ICS cultures, plates were incubated for 1 hour at 37°C, after which BD Golgi-Plug and GolgiStop were added to each well and the cultures were incubated for an additional 5 hours. Cells were then stained for CD4 and CD8, fixed, and permeabilized with BD Cytofix/Cytoperm solution, then washed with 1 x BD Perm/Wash buffer and stained for CD3, CD4, CD8, IL2, TNF, IFNγ, and Live/Dead Violet. Cells were analyzed on BD LSRII and BD LSRFortessa flow cytometers using FACS Diva software. Data were analyzed using the FlowJo software (TreeStar).

Live/Dead (Invitrogen). Cells were analyzed on a BD LSRFortessa flow cytometer using FACS Diva software. Data were analyzed using FlowJo software (TreeStar).

TLR polymorphisms

Coding sequences were obtained from PBMCs using PCR and Sanger sequencing on genomic DNA. Primers were designed to cover the coding sequences plus at least 10 nucleotides in the intron region on both ends. Primer extension sequencing was performed by GENEWIZ, Inc. using Applied Biosystems BigDye version 3.1. Both forward and reverse strands were sequenced. The reactions were then run on the Applied Biosystem's 3730xl DNA Analyzer. The sequencing data were analyzed with Lasergene SeqMan software (DNASTAR) to detect any mutations compared with the genomic DNA reference sequence.

Statistical analyses

Linear mixed-effects model analyses of repeated measures were used to compare the T-cell responses over time on the placebo (arm A) and resiquimod (arm B). Repeat measurements were obtained from blood drawn on the day of the first vaccine injection, 8 days after the first, second, third, and fourth (final) vaccine injection, and 2 to 4 weeks after the final injection. A first-order autoregressive structure with heterogeneous variances was used for the covariance structure of the residuals. A Mann–Whitney test was used to compare plasma antibody titers at various time points between arms A and B. An exact logistic regression model was used for comparing the odds of developing NY-ESO-1-specific CD8⁺ T-cell responses between patients positive for the TLR7 SNP rs179008 and patients who tested negative for this SNP.

Results

Patient characteristics

A total of 6 patients were sequentially enrolled in part I of the study, 3 patients in each cohort (Fig. 1). All patients had resected cutaneous melanoma, except for 1 patient who had resected ocular melanoma. A total of 20 patients were enrolled in part II of the study. Patients were randomized into two arms—arm A (placebo) and arm B (resiquimod). All patients had resected malignant melanoma (Table 1). Expression of NY-ESO-1 in the resected tumor was not required for study entry, and specimens for immunohistochemical (IHC) analysis were available in only 4 of 6 patients in part I and 10 of 20 patients in part II. Consistent with the reported frequencies, 1 patient in part I and 3 patients in part II [arm A (placebo) = 1, arm B (resiquimod) = 3] had tumors that expressed NY-ESO-1 (23).

Table 1. Pretreatment patient characteristics

<table>
<thead>
<tr>
<th>Sex</th>
<th>Part I</th>
<th>Part II</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A</td>
<td>B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>3</td>
<td>6</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>3</td>
<td>2</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Age (y), median (range)</td>
<td>66 (28–74)</td>
<td>72 (29–81)</td>
<td>58 (37–67)</td>
<td></td>
</tr>
<tr>
<td>AJCC staging</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IB</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IA</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IB</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>IIIC</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>NY-ESO-1 expression in tumors</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>
were no grade 4 or 5 adverse events. The most commonly reported
four vaccine injections and gel applications. One patient from part
cohort 2 (3

injections and gel applications. The dose of resiquimod used in
dose-limiting toxicity. Six of 6 patients completed all four vaccine
vaccine combinations were generally well tolerated. Dose esca-
lration in part I of the study proceeded as planned with no reported
Safety
Constitutional
Chills
2 (8)
Fatigue
16 (62)
Musculoskeletal
Arthralgia
10 (38)
Myalgia
4 (16)
Gastrointestinal
Emesis
2 (8)
Injection site reactions
Injection site necrosis
1 (4)
Erythema
24 (92)
Granuloma
26 (100)
Skin Induration
23 (89)
Rash (pruritic)
24 (92)
Rash (nonpruritic)
6 (23)
Urticaria
18 (69)
Neurological
Headache
4 (15)
Dizziness
4 (15)

<table>
<thead>
<tr>
<th>Toxicity grade</th>
<th>n (%)</th>
<th>n (%)</th>
</tr>
</thead>
</table>
| Constitutional
Chills | 2 (8) | 0 |
| Fatigue | 16 (62) | 0 |
| Musculoskeletal
Arthralgia | 10 (38) | 0 |
| Myalgia | 4 (16) | 0 |
| Gastrointestinal
Emesis | 2 (8) | 0 |
| Injection site reactions
Injection site necrosis | 1 (4) | 0 |
| Erythema | 24 (92) | 0 |
| Granuloma | 26 (100) | 0 |
| Skin Induration | 23 (89) | 0 |
| Rash (pruritic) | 24 (92) | 0 |
| Rash (nonpruritic) | 6 (23) | 0 |
| Urticaria | 18 (69) | 0 |
| Neurological
Headache | 4 (15) | 0 |
| Dizziness | 4 (15) | 0 |

NOTE: n = number of patients experiencing the respective toxicity.

NY-ESO-1-specific cellular responses
Figure 3A shows representative flow cytometry results after IVS.
NY-ESO-1-specific CD4\textsuperscript{+} T-cell responses were induced in 6 of 8 (75%) patients in arm A and 10 of 12 (83%) patients in arm B (Fig. 3B). Pretreatment NY-ESO-1–specific CD4\textsuperscript{+} T-cell responses were detected in 4 of 8 (50%) patients in arm A and 2 of 12 (17%) patients in arm B; vaccination increased the frequencies of these CD4\textsuperscript{+} T-cell responses in all patients. In responders, NY-ESO-1–
specific CD4\textsuperscript{+} T cells were detectable after the second and third
cycle of vaccination. NY-ESO-1–specific CD8\textsuperscript{+} T-cell responses were
detected in 3 of 12 (25%) patients in arm B (Fig. 3C). Of note, 2 of the patients with NY-ESO-1–specific CD8\textsuperscript{+} T-cell responses also had tumors with documented NY-ESO-1 expres-
sion (Table 3). The majority of NY-ESO-1–specific CD4\textsuperscript{+} and
CD8\textsuperscript{+} T cells were polyfunctional as they secreted both IFN\textgamma and
TNF\alpha, with a small proportion also secreting IL2. Results of the mixed
model analyses showed that there was no significant
difference between study arms for mean changes from baseline
to posttreatment evaluations for NY-ESO-1–specific CD4\textsuperscript{+} and
CD8\textsuperscript{+} T-cell responses.

Mapping of reactivity to vaccine-induced T-cell responses using
individual peptides showed induction of NY-ESO-1–specific
T-cell responses to several peptide epitopes (Fig. 3D). Vaccine-
induced CD4\textsuperscript{+} T-cell responses mapped mostly to the central and
terminal regions of NY-ESO-1 protein, consistent with results
from previous studies (11, 24). CD4\textsuperscript{+} T-cell responses to peptides
81–100, 101–120, and 119–143 were detected in several patients
(4 of 8 patients in arm A and 10 of 12 patients in arm B). Although
not feasible in all cases due to limited cell quantities, NY-ESO-1–
specific CD8\textsuperscript{+} T-cell responses were mapped to the central and C-
terminal region of the protein. More specifically, CD8\textsuperscript{+} T-cell
responses were mapped to peptides 81–100 and 161–180, which
is consistent with results from previous studies (24, 25).

Effect of CD25 depletion on NY-ESO-1–specific cellular
responses
Although designed to induce antigen-specific T-cell responses
with effector function, vaccines have also been reported to induce
Tregs (26, 27). We also considered that circulating Tregs might
compromise the induction of antigen-specific T-cell responses as a
result of vaccination. To assess these possibilities, we depleted
CD25\textsuperscript{+} cells from bulk PBMCs before positive selection of CD4\textsuperscript{+}
and CD8\textsuperscript{+} T cells and IVS. CD8\textsuperscript{+} T-cell responses were
unmasked in an additional 2 patients (1 of 8 patients in arm A and 1 of 9
patients in arm B). CD4\textsuperscript{+} T-cell responses were unmasked in an
additional 4 patients (2 of 2 patients in arm A and 2 of 2 patients
in arm B). Figure 4A shows a representative example of NY-ESO-
one-specific CD4\textsuperscript{+} T-cell responses in a patient before and after
CD25 depletion. The effect of CD25 depletion was not consistent
in all patients as some patients had no effect or only slightly
amplified responses after CD25 depletion. Interestingly, we also
detected NY-ESO-1–specific CD4\textsuperscript{+} T-cell responses in prevaccine
samples in 3 of 4 patients in arm B whose responses became
detectable after CD25 depletion.

Although CD25 depletion resulted in the ability to detect
T-cell responses in a subset of patients, CD25 expression in
CD4\textsuperscript{+} T cells was similarly elevated pre- and posttreatment
in patients with detectable NY-ESO-1–specific CD4\textsuperscript{+} T-cell
response as compared with patients with no detectable
NY-ESO-1–specific CD4\textsuperscript{+} T-cell response (Fig. 4B). Examination
of the CD25-expressing cells revealed that CD25 was

NY-ESO-1–specific humoral responses
Antibody responses to NY-ESO-1 were induced in all patients
who were seronegative before vaccination regardless of the pres-
ence or dose of resiquimod (Fig. 2A). The majority of patients
seroconverted after receiving the second or third vaccine. Anti-
body titers were not significantly different between patients in
arms A and B at screening, C2D8, and follow-up visits (Fig. 2B).
Pretreatment antibody responses to NY-ESO-1 were detected in 3
of 20 (15%) patients, and all 3 patients (arm A = 1; arm B = 2)
showed substantial increases in antibody titers after vaccination.
Only 1 (arm B) of 4 patients whose tumors were NY-ESO-1–
had pretreatment anti–NY-ESO-1 antibodies. This patient had the
highest anti–NY-ESO-1 titers after vaccination compared with
those of all study patients (Table 3).

Mapping of epitopes recognized by vaccine-induced NY-ESO-1
antibodies was performed by ELISA using three overlapping
long peptides covering the NY-ESO-1 protein (peptide 1: 1–68;
peptide 2: 57–124; peptide 3: 113–180). As shown in Fig. 2C,
specific antibody responses induced by the vaccine were detected
in all three regions covered by the long peptides in both arms A
and B. Consistent with previous studies, most of these antibody
responses mapped to peptides 1 and 2 corresponding to the
N-terminal end and central regions of NY-ESO-1 (22).

NY-ESO-1 Protein and Montanide ± Resiquimod in Melanoma
coexpressed with CTLA-4 but not with PD-1, TIM-3, and FoxP3 in CD4+ T cells, possibly indicative of the specific presence of inhibitory or "exhausted" cells (Fig. 4C).

Role of TLR polymorphisms in response to vaccination

Accumulating evidence suggests an important role for single-nucleotide polymorphisms (SNP) within TLR genes as determinants of disease susceptibility and severity (28). Furthermore, SNPs may influence response and outcome to vaccination with TLR ligands (29). We investigated the role of TLR7 and TLR8 SNPs in the ability of a patient to respond to the vaccine regimen. Two SNPs in TLR7 (rs179008 and rs864058) and six SNPs in TLR 8 (rs3764880, rs2159377, rs5744080, rs2407992, rs3747414, and rs2109135) were detected. Of these eight SNPs, TLR8 SNP rs3764880 and TLR7 SNP rs179008 were nonsynonymous.

The nonsynonymous TLR8 SNP rs3764880 was detected in 7 of the 20 (35%) patients in arms A and B (Table 3). This SNP has been shown to affect the coding region of TLR8, leading to differential activation of NF-κB (30); in addition, it was found to be associated with protection against tuberculosis (31) and increased risk for systemic lupus erythematosus (32). In our study, no association was observed between vaccine-induced immune responses and the presence of SNP rs3764880. The TLR7 SNP rs179008 has been associated with accelerated HIV-1 disease progression (33) and decreased risk for Hodgkin disease (34). SNP rs179008 was detected in the 3 patients in arm B who had detectable NY-ESO-1–specific CD8+ T-cell responses and in 1 patient in arm A who did not have a detectable NY-ESO-1–specific CD8+ T-cell response (Table 3). When adjusted for cohort, the estimated frequency of a CD8+ T-cell response for patients carrying SNP rs179008 was almost 20 times that of patients who did not have this SNP (OR, 19.7; 95% CI, 1.11–999; P = 0.04).

Clinical outcome

The last clinical follow-up for this study was performed in January 2014. In study part I, 1 patient has died, 1 patient is alive with disease, 1 patient has undergone further resection and has remained without evidence of disease, and 3 patients have remained without evidence of disease. In part II of the study, 1 patient was lost to follow-up (arm A), 5 patients have died (arm
A = 2; arm B = 3). 1 patient is alive with disease (arm A), 6 patients have undergone further resection and have remained without evidence of disease (arm A = 1; arm B = 5), and 7 patients have remained without evidence of disease (arm A = 3; arm B = 4; Table 3). Analysis of time to progression at the end of the study and at the last follow-up did not reveal any significant differences between study arms.

**Discussion**

NY-ESO-1 is a commonly expressed tumor-specific antigen that can induce both humoral and cellular immune responses in patients with cancer. Studies have evaluated the immunogenicity of NY-ESO-1 antigens in melanoma and other solid tumors in combination with Montanide or/and TLR agonists. Montanide is considered an effective immune adjuvant because of its ability to create a depot effect, which results in slow release of antigens and recruitment of APCs to the injection site. TLR agonists, such as resiquimod (TLR7/8), CpG (TLR9), and poly-ICLC (TLR3), have strong immune adjuvant properties because of their ability to trigger signaling pathways and transcription programs, resulting in the activation of key molecules associated with inflammation and immunity (in particular NF-κB and type I interferons). Both Montanide and a number of TLR agonists have been shown to induce humoral and cellular immune responses; addition of the TLR3 agonist poly-ICLC to Montanide in an NY-ESO-1 peptide vaccine was shown to induce stronger, more frequent and earlier-onset T-cell and humoral responses in patients with advanced ovarian cancer (24, 35). However, randomized studies comparing the adjuvant effect of Montanide alone versus Montanide in combination with TLR agonists have not been performed. To our knowledge, our study is the first to compare Montanide with and without the addition of a TLR agonist as adjuvant in an NY-ESO-1 protein vaccine in a randomized trial.

We show that NY-ESO-1 protein in combination with Montanide alone or Montanide plus resiquimod is both safe and immunogenic in patients with resected high-risk melanoma. All patients developed anti-NY-ESO-1 IgG antibody titers. The magnitude of antibody titers was notable: 6 of 12 (50%) patients vaccinated with NY-ESO-1 protein in Montanide plus resiquimod exhibited very high (≥100,000) IgG titers, whereas 2 of 8 patients (25%) had similarly high titers in the Montanide-only cohort. No difference in the kinetics of antibody responses was seen when resiquimod was added to Montanide, in contrast with an earlier onset of IgG antibodies observed in patients immunized with NY-ESO-1 peptides with Montanide plus poly-ICLC compared with that with only Montanide (24).

Using short-term *in vitro* restimulation assays, CD4**+** T-cell responses were induced in the majority of patients; no differences in the rates or magnitude of the responses were seen with the addition of resiquimod. In contrast, CD8**+** T-cell responses, in addition to humoral and CD4**+** T-cell responses (integrated responses), were induced, albeit in a relatively small subset of patients (3 of 12, 25%) who were vaccinated with NY-ESO-1 plus both Montanide and resiquimod. Of note, all 3 patients with integrated antibody, CD4**+**, and CD8**+** T-cell responses had substantially higher IgG antibody titers (at least 3 times higher than non-CD8**+** T-cell responders). We have previously shown a trend for the correlation of NY-ESO-1 protein–specific CD8**+** T-cell responses with higher NY-ESO-1–specific antibody titers (36). In that study, efficient cross-presentation of recombinant NY-ESO-1 protein by autologous DCs (as measured by IFNγ secretion of vaccine-induced CD8**+** T cells) was only seen when the protein was preincubated either with murine NY-ESO-1–specific monoclonal Ab (ES121) or with postvaccine serum. The strikingly higher anti-NY-ESO-1 IgG antibody titers observed in the 3 CD8**+** T-cell responders and the observation that none of the CD8**+** T-cell responses were seen before the development of vaccine-induced antibodies suggest that these antibodies promoted cross-presentation through the formation of immune complexes (37, 38).

In a previous study, we demonstrated that NY-ESO-1 protein, given intradermally along with topical imiquimod and antitumor vaccine. Montanide alone or Montanide plus resiquimod is both safe and immunogenic in patients with resected high-risk melanoma. All patients developed anti-NY-ESO-1 IgG antibody titers. The magnitude of antibody titers was notable: 6 of 12 (50%) patients vaccinated with NY-ESO-1 protein in Montanide plus resiquimod exhibited very high (≥100,000) IgG titers, whereas 2 of 8 patients (25%) had similarly high titers in the Montanide-only cohort. No difference in the kinetics of antibody responses was seen when resiquimod was added to Montanide, in contrast with an earlier onset of IgG antibodies observed in patients immunized with NY-ESO-1 peptides with Montanide plus poly-ICLC compared with that with only Montanide (24).

Using short-term *in vitro* restimulation assays, CD4**+** T-cell responses were induced in the majority of patients; no differences in the rates or magnitude of the responses were seen with the addition of resiquimod. In contrast, CD8**+** T-cell responses, in addition to humoral and CD4**+** T-cell responses (integrated responses), were induced, albeit in a relatively small subset of patients (3 of 12, 25%) who were vaccinated with NY-ESO-1 plus both Montanide and resiquimod. Of note, all 3 patients with integrated antibody, CD4**+**, and CD8**+** T-cell responses had substantially higher IgG antibody titers (at least 3 times higher than non-CD8**+** T-cell responders). We have previously shown a trend for the correlation of NY-ESO-1 protein–specific CD8**+** T-cell responses with higher NY-ESO-1–specific antibody titers (36). In that study, efficient cross-presentation of recombinant NY-ESO-1 protein by autologous DCs (as measured by IFNγ secretion of vaccine-induced CD8**+** T cells) was only seen when the protein was preincubated either with murine NY-ESO-1–specific monoclonal Ab (ES121) or with postvaccine serum. The strikingly higher anti-NY-ESO-1 IgG antibody titers observed in the 3 CD8**+** T-cell responders and the observation that none of the CD8**+** T-cell responses were seen before the development of vaccine-induced antibodies suggest that these antibodies promoted cross-presentation through the formation of immune complexes (37, 38).

In a previous study, we demonstrated that NY-ESO-1 protein, given intradermally along with topical imiquimod and
without Montanide, induced both humoral and CD4+ T-cell responses in patients with high-risk melanoma (11). Acknowledging the limitations of cross-trial comparisons and the additional TLR8 agonistic activity of resiquimod, it appears that the more controlled antigen release mediated by Montanide may have resulted in the substantially higher NY-ESO-1-specific antibody titers and, either independently or as a result of cross-presentation facilitated by antibodies, in the CD8+ T-cell responses seen in a proportion of patients. Furthermore, the higher CD8+ T-cell response rate observed with NY-ESO-1 protein in combination with CpG and Montanide injected s.c. suggests that topical application of the TLR agonist may be inferior to application into deeper skin layers because only epidermal DC, such as Langerhans cells (LC), may be directly exposed to the inflammatory stimulus. This is demonstrated in the lack of statistically significant difference when comparing recruitment of immune cells at injection biopsies taken from patients in arm A versus arm B (data not shown). DC trafficking from the skin to the draining lymph nodes is a complex process involving the need to detach from structural tissue elements, migration through the basement membrane and extracellular matrix, and traversing the afferent lymphatic endothelium (39, 40). Furthermore, diverse DC populations reside in different layers of the skin. It is therefore conceivable that s.c. deposit of a TLR agonist may reach DC populations, such as the CD141+ DC subset, which plays a key role in cross-presentation of protein antigens (41), and which may be more easily mobilized and migrate more promptly to draining lymph nodes leading to more efficient encounter with T cells.

Vaccination with NY-ESO-1 full-length protein genetically fused to a fully human anti-DEC-205 monoclonal antibody given with topical resiquimod generated T-cell responses (as measured by IFNγ ELISPOTS after IVS of PBMCs) in 10 of 19 (53%) patients with advanced malignancies. Acknowledging the limitations of a cross-trial comparison, the higher rate of T-cell responses in the current study indicates that soluble NY-ESO-1 antigen given with Montanide alone or Montanide plus resiquimod may not be inferior to antigen delivery through a DEC-205-targeted approach (38).

Epitope mapping studies with three long peptides revealed a predominance of antibody reactivity directed against the N-terminal and central portions of NY-ESO-1, consistent with results from previous reports of both spontaneous and vaccine-induced NY-ESO-1 antibody titers in patients with cancer (1, 11, 36). Determinant mapping using a library of overlapping 20- to 22-mer overlapped peptides and CD8+ T-cell responses directed against epitopes essentially spanning the entire central and C-terminal regions of the NY-ESO-1 protein. This broad and dense pattern of immunogenicity is expected from previous reports assessing both spontaneous and vaccine-induced T-cell responses to NY-ESO-1 (1, 11, 24, 36).}

Figure 3. NY-ESO-1-specific cellular responses. A, PBMCs were separated into CD4 and CD8 T-cell fractions and in vitro stimulated with NY-ESO-1 overlapping peptides. Responses to NY-ESO-1 were evaluated by IFNγ, IL2, and TNF after 14 days for CD8 T-cell fractions and 21 days for CD4 T-cell fractions. Patients with NY-ESO-1–specific CD4+ (left) and CD8+ (right) T-cell responses pre- and posttreatment are shown. B and C, summary of NY-ESO-1–specific CD4+ (B) and CD8+ (C) T-cell responses in study part II patients pre- and postvaccination. Top, responses by patients in arm A; and bottom, responses by patients in arm B. D, NY-ESO-1–specific T-cell responses were mapped using individual overlapping peptides covering the entire NY-ESO-1 protein sequence.
selection in our study resulted in detection of NY-ESO-1–specific T-cell responses in several patients; however, this effect was not consistent in all patients. Several observations therefore support an argument against a general effect of NY-ESO-1–specific Treg expansion by the vaccine: the heterogeneity of “unmasking” T-cell responses with CD25+ cell depletion across patients; the lack of statistically significant differences in CD25 expression between patients in whom NY-ESO-1–specific responses were unmasked by CD25+ depletion and those in whom they were not; the absence of an increase in CD25 expression after vaccination; and the fact that both NY-ESO-1–specific CD4+ and CD8+ T-cell responses were observed without CD25 depletion.

Using SNP analysis, we examined possible associations of TLR7 and TLR8 polymorphisms with immune response to the NY-ESO-1 vaccine. In the current study, 4 of 20 (20%) patients in part II were carriers of the nonsynonymous TLR7 SNP rs179008, which is consistent with the prevalence of this SNP in a large (n > 500) control group of predominantly male, Caucasian individuals in an HIV study (33). Notably, this SNP was detected in all 3 patients who developed CD8+ T-cell responses after vaccination with NY-ESO-1 and Montanide plus resiquimod. The other patient who also had this particular SNP did not develop CD8+ T-cell responses after vaccination with NY-ESO-1 and Montanide plus placebo. The observed statistically significant correlation between the TLR7 SNP rs179008 and CD8+ T-cell response induced by a vaccine containing the respective TLR agonist raises the possibility that SNP analysis may be useful to select appropriate vaccine adjuvants based on TLR polymorphisms in patients with cancer. The SNP rs179008 results in alteration of a Gln to a Leu residue in the signal peptide sequence of TLR7. In silico analysis using SignalP previously predicted that the amino acid change to Leu at position 11 extends the hydrophobic region of the signal sequence, possibly affecting the processing of TLR7 (45). It is conceivable that altered TLR7 processing could lead to enhanced sensitivity of TLR7, potentially affecting the production of mediators for inflammation and immunity.

In conclusion, vaccination with NY-ESO-1 protein given in combination with Montanide with or without topical resiquimod induces NY-ESO-1–specific humoral and CD4+ T-cell responses. CD8+ T-cell responses were only induced in a subset of patients vaccinated with NY-ESO-1 combined with Montanide and resiquimod. These immune responses were targeted at multiple epitopes of NY-ESO-1, primarily in the N-terminal portion for the antibody responses and central/C-terminal portions for the cellular responses. Recent observations of NY-ESO-1 immune responses as a predictor of objective tumor
responses to CTLA-4 blockade and the finding that CTLA-4 blockade can induce or enhance polyfunctional CD4+ and CD8+ T-cell responses (2, 46) provide the rationale for concurrent therapy using NY-ESO-1 vaccines in combination with immune checkpoint blockade or other agents mediating relief from immune suppression in patients with melanoma and other cancers. An ongoing study using NY-ESO-1 vaccine and CTLA-4 blockade in melanoma (NCT01810016) is testing this hypothesis.

Disclosure of Potential Conflicts of Interest

S. Gnjatic has ownership interest in NY-ESO-1–related patents. J. Escalon is a senior nurse practitioner coordinator at Mount Sinai Hospital. P.A. Ott is a consultant/advisory board member for Amgen and Bristol-Myers Squibb. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: R.L. Sabado, A. Pavlick, R.M. Holman, J. Goldberg, S. Adams, R. Venhaus, N. Bhardwaj


Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): R.L. Sabado, A. Pavlick, S. Gnjatic, C.M. Cruz, J. Vengco, F. Hasan, L. Chiriboga, R.M. Holman, J. Escalon, C. Escano, A. Jungbluth, P.A. Ott


Writing, review, and/or revision of the manuscript: R.L. Sabado, A. Pavlick, S. Gnjatic, J.P. Vilasolos, L. Rolnitzky, J. Goldberg, J. Mandelli, S. Adams, R. Venhaus, P.A. Ott, N. Bhardwaj

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): R.L. Sabado, S. Gnjatic, C.M. Cruz, J. Vengco, R.M. Holman, C. Muren, E. Yepes, R. Venhaus, P.A. Ott, N. Bhardwaj

Study supervision: J. Escalon, C. Escano, E. Yepes, R. Venhaus, N. Bhardwaj

Other (laboratory technician in the Vaccine and Cell Therapy Lab during this clinical trial and prepared vaccine and conducted immune monitoring along with the other technicians): M. Spadaccia

Other (compliance and regulatory): R.M. Holman

Other (data collection): D. Sharpe

Other (immunohistochemical analysis of NY-ESO-1 protein expression): A. Jungbluth

Other (clinical monitoring and data collection capabilities): L. Pan

Other (clinical and medical monitoring): R. Venhaus

Acknowledgments

The authors thank Christine Sedra for excellent technical assistance.

Grant Support

This study was sponsored and funded by the Ludwig Institute for Cancer Research with a supplemental grant from the Cancer Research Institute as part of the Cancer Vaccine Collaborative. S. Gnjatic was supported by a grant from the Cancer Vaccine Collaborative for Immunological Monitoring.

D. Goldberg and L. Rolnitzky were supported by 5 P30 CA16087 New York University Cancer Center Support Grant 5 P30 CA16087. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

References


NY-ESO-1 Protein and Montanide ± Resiquimod in Melanoma

Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma
Rachel Lubong Sabado, Anna Pavlick, Sacha Gnjatic, et al.

Access the most recent version of this article at: doi:10.1158/2326-6066.CIR-14-0202

This article cites 46 articles, 19 of which you can access for free at: http://cancerimmunolres.aacrjournals.org/content/3/3/278.full#ref-list-1

This article has been cited by 2 HighWire-hosted articles. Access the articles at: http://cancerimmunolres.aacrjournals.org/content/3/3/278.full#related-urls

Sign up to receive free email-alerts related to this article or journal.
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.